PNB Vesper life science Pvt Ltd, is a leading Indian Pharma Research company with a vision to “work towards a healthier World by developing novel, safe, and affordable medicines to prevent and treat unmet medical needs”.
PNB Vesper has today received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2b Clinical trial of their propriety drug PNB-001 (GPP-Baladol®) in testing COVID-19 patients. PNB 001 may be the first New Chemical Entity in the world for testing in COVID-19 patients.
The company has filed the Clinical trial application with DCGI for the Phase 2 Clinical Trials and the study will be completed in 60 days. The study will be conducted in 40 Covid-19 positive patients at BMJ Medical College, Pune who are moderate patients on oxygen support. The effect of PNB 001 will be compared with DEXAMETHASONE, currently the most popular medicine in COVID-19 treatment in the world. A larger population, Approximately 350 Covid 19 patients will be enrolled Across the Country in 6 medical Colleges the Phase 3 Clinical trials after reviewing the phase 2 clinical trial results. The molecule has already been patented and the related Intellectual Property Rights (IPRs) have been secured by PNB VESPER in the US, Europe and rest of the world.